Development of bilaminar dermal matrix of bovine collagen impregnated with bacteriostatic agent

• Grant number: 22/04726-5
• Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
• Start date: November 01, 2022
• End date: April 30, 2025
• Field of knowledge: Health Sciences - Medicine - Surgery
• Principal Investigator: Nathália Ferreira Flausino
• Grantee: Nathália Ferreira Flausino
• Company: MLA Suprimentos Médicos Ltda
• CNAE: Fabricação de instrumentos e materiais para uso médico e odontológico e de artigos ópticos ; Comércio atacadista de instrumentos e materiais para uso médico, cirúrgico, ortopédico e odontológico
• City: Jundiaí
• Associated researchers: Daniel Komatsu ; Eliana Aparecida de Rezende Duek ; Flavia Maria Morais Pedrini ; Graziella Ribeiro dos Santos ; Jose Edson Gandolfi
• Associated research grant: 19/22977-2 - Development of bilaminary dermal matrix of bovine collagen impregnated with bacteriostatic agent, AP.PIPE
• Associated scholarship(s): 23/10390-2 - DEVELOPMENT OF BILAMINAR DERMAL MATRIX OF BOVINE COLLAGEN IMPREGNATED WITH BACTERIOSTATIC AGENT, BP.TT; 23/09870-0 - DEVELOPMENT OF BILAMINAR DERMAL MATRIX OF BOVINE COLLAGEN IMPREGNATED WITH BACTERIOSTATIC AGENT, BP.TT; 23/05367-1 - DEVELOPMENT OF BILAMINAR DERMAL MATRIX OF BOVINE COLLAGEN IMPREGNATED WITH BACTERIOSTATIC AGENT, BP.TT; + associated scholarships 23/03428-3 - DEVELOPMENT OF BILAMINAR DERMAL MATRIX OF BOVINE COLLAGEN IMPREGNATED WITH BACTERIOSTATIC AGENT, BP.TT; 22/14471-4 - DEVELOPMENT OF BILAMINAR DERMAL MATRIX OF BOVINE COLLAGEN IMPREGNATED WITH BACTERIOSTATIC AGENT, BP.TT; 22/14512-2 - DEVELOPMENT OF BILAMINAR DERMAL MATRIX OF BOVINE COLLAGEN IMPREGNATED WITH BACTERIOSTATIC AGENT, BP.TT - associated scholarships

Abstract

The interest in synthetic or biological materials that can be used in the manufacture of matrices is a constant object of study. Such studies aim at complexity and intensive treatment2, hospital care treatment (Shahrokhi treatment) In this sense, a bilaminar matrix was developed in Phase 1 of PIPE, where the 1st layer is composed of silicone and the 2nd is composed of collagen, PEG and glycerol, which were responsible for providing greater stability to collagen. In this layer by collagen, PEG was focused and better in glycerol concentration, it was composed to improve glycerol concentration, so as to inhibit the growth of common bacteria in growth for the growth of common bacteria in growth for the growth of common bacteria in which involves the growth of bacteria. From the assays, a stipulated concentration was 100 µg/ml.It is important to mention that, in dermal matrices, the mechanical and physicochemical properties must also be developed so that such devices are easily handled during their implantation and can be perfectly accommodated on the wound bed. The bilaminar matrix developed in the 1st phase proved to be quite manageable, which makes it easily adaptable to surfaces, which are often irregular. Thus, the essential characteristics for the applicability of dermal matrices were fully satisfied, namely: biocompatibility, flexibility, prevention of fluid loss and acting as a barrier to bacterial invasion. Currently, the dermal matrices that exist on the market are made up of a layer of bovine collagen with elastin (monolaminar) and another with a layer of bovine or porcine collagen without elastin covered by a silicone membrane (bilaminar), called one-time and two-stage matrices. , respectively. Therefore, the challenge of the project consisted in optimizing the design of this type of dermal matrix so that the inner lamina, which will be in direct contact with the injured region, was constituted by collagen, whose role is to act as a framework for cell migration, while the outer layer, composed of silicone, has the function of acting as a barrier against the loss of fluids and the entry of microorganisms. As a differential, the incorporation of Triclosan, a bacteriostatic agent widely used by the industry, aimed at greater efficiency in protecting bacteria. This defense aims to improve the regeneration process against the dermal matrices currently available, since one of the reasons for the loss of the dermal matrix, after placing it on the lesion, is precisely the susceptibility to infections to which they are subject ( Quezada, 2009; Pharm C, 2007; Balasubramani 2001; Rodas, 2004). These are promising results, which denote the potential of the matrix and the importance of its broader exploration in a 2nd phase of the PIPE. (AU)